Anti-uPAR/PLAUR Antibody (APC), Mouse Monoclonal

1/1
Price:
Size:
Number:

Anti-uPAR/PLAUR Antibody (APC), Mouse Monoclonal 产品信息

产品名称
Anti-uPAR/PLAUR Antibody (APC), Mouse Monoclonal
经验证的应用
FCM
交叉反应
Reacts with: Human
特异性
Human uPAR/PLAUR
免疫原
Recombinant Human PLAUR/CD87 Protein (Catalog#10925-H08H)
制备方法
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human PLAUR / CD87 (rh PLAUR / CD87; Catalog#10925-H08H; Q03405-1; Met1-Arg303) and conjugated with APC under optimum conditions, the unreacted APC was removed.
来源
Monoclonal Mouse IgG1 Clone #09
纯化
Protein A
缓冲液
Aqueous solution containing 0.5% BSA and 0.09% sodium azide
偶联物
APC
浓度
10 μl/Test, 0.1 mg/ml
状态
Liquid
运输方式
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
储存条件
This antibody can be stored at 2℃-8℃ for twelve months without detectable loss of activity. Protected from prolonged exposure to light. Do not freeze ! Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.

Anti-uPAR/PLAUR Antibody (APC), Mouse Monoclonal 图片

Flow cytometric analysis of human UPAR(CD87) expression on human whole blood granulocytes. Human whole blood granulocytes were stained with APC-conjugated anti-Human UPAR(CD87). The histogram were derived from gated events with the forward and side light-scatter characteristics of viable granulocytes.

Anti-uPAR/PLAUR Antibody (APC), Mouse Monoclonal: 别称

Anti-CD87 Antibody; Anti-U-PAR Antibody; Anti-UPAR Antibody; Anti-URKR Antibody

uPAR/PLAUR 背景信息

Urokinase plasminogen activator (uPA) and/or its receptor (uPAR) are essential for metastasis, and overexpression of these molecules is strongly correlated with poor prognosis in a variety of malignant tumours. uPAR and uPA levels in both resected tumor tissue and plasma are of independent prognostic significance for patient survival in several types of human cancer. This system has classically been thought to drive tumor progression by mediating directed extracellular proteolysis on the surface of migrating or invading cells, and intervening with this proteolysis by targeting uPAR has been proposed to represent a novel approach for inhibiting tumor progression. uPAR, also known as PLAUR or CD87, has been implicated in the growth, metastasis, and angiogenesis of several solid and hemotologic malignancies. uPAR is a highly glycosylated, 55-60kDa integral membrane protein linked to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor. It is part of a cell surface system that also consists of the serine protease uPA and several specific inhibitors (plasminogen activator inhibitors 1 and 2). Additionally, the analysis of CD87 (urokinase-type plasminogen activator receptor - uPAR) expression has a potential role in the diagnostic or prognostic work-up of several hematological malignancies, particularly acute leukemia and multiple myeloma.
全称
plasminogen activator, urokinase receptor
参考文献
  • Romer J, et al. (2004) The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des. 10(19): 2359-76.
  • Bn MC, et al. (2004) CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review. Leukemia. 18(3): 394-400.
  • Pillay V, et al. (2007) The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol. 25(1): 33-9.
  • Mazar AP. (2008) Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res. 14(18): 5649-55.
添加购物车成功! 添加购物车失败!请再次尝试 正在更新购物车,请稍后 U.S.A.